DHEC discusses vaccination research and COVID-19 vaccine safety concerns in South Carolina

In a recent meeting of the South Carolina Senate Medical Affairs Committee held on April 3, 2025, discussions centered around the ongoing research and public health implications of COVID-19 vaccines, particularly concerning their safety and effectiveness. The meeting highlighted the importance of collaboration between state health agencies and academic institutions, as well as the need for transparency regarding vaccine-related risks.

One of the key topics addressed was the proposed research project from the University of South Carolina (USC) that aims to investigate potential issues related to the COVID-19 vaccine. A committee member expressed concern over the lack of direct communication with the researcher involved, emphasizing the urgency of exploring any potential red flags associated with the vaccine. The representative from the Department of Health and Environmental Control (DHEC) acknowledged reaching out to USC but noted that they had not received updates on the project's progress.

The committee also discussed a bulletin released by the Florida Surgeon General, which raised alarms about the waning effectiveness of mRNA COVID-19 vaccines and associated risks, including myocarditis. The DHEC representative confirmed that they provide informed consent warnings about cardiac side effects, particularly for younger individuals, but did not issue a bulletin similar to Florida's. This raised questions about the adequacy of communication regarding vaccine risks to the public.

Further discussions delved into the scientific literature surrounding the presence of DNA in vaccines, with the DHEC representative asserting that current evidence suggests minimal risk if DNA is present. However, they acknowledged the need for further research to address public concerns.

The meeting also touched on the agency's past actions regarding vaccine rollout, particularly for children aged 5 to 11. The DHEC representative defended the agency's decisions, stating that at the time, there was no known link between vaccines and cardiac side effects in younger populations.

Overall, the meeting underscored the ongoing debate surrounding vaccine safety and the importance of thorough research and communication in public health policy. As the committee continues to navigate these complex issues, the implications for public trust and health outcomes remain significant. Future steps will likely involve closer collaboration with research institutions and a commitment to transparency in addressing vaccine-related concerns.